Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 6/20 | 0.54 |
| ▸ | CCR2 | P41597 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 3/20 | 0.49 |
| ▸ | DRD4 | P21917 | 3/20 | 0.49 |
| ▸ | HTR2A | P28223 | 2/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 7/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 7/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 6/20 | 0.46 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3460812 | 0.89 | ATR (0.57) | ATRDRD2DRD4HTR2APIK3CD | |
| SCHEMBL3461007 | 0.88 | DRD2 (0.65) | ATRDRD2DRD4HTR2AACVR1 | |
| SCHEMBL4251697 | 0.88 | DRD2 (0.65) | ATRDRD2DRD4HTR2AACVR1 | |
| SCHEMBL3462081 | 0.88 | DRD2 (0.65) | ATRDRD2DRD4HTR2AACVR1 | |
| SCHEMBL3907494 | 0.84 | ATR (0.47) | ATRPIK3CDPIK3CAPIK3CGPIK3CB | |
| SCHEMBL3907501 | 0.84 | ATR (0.47) | ATRPIK3CDPIK3CAPIK3CGPIK3CB | |
| SCHEMBL3462402 | 0.83 | ATR (0.67) | ATRDRD2DRD4ACVR1 | |
| SCHEMBL3461651 | 0.81 | ATR (0.51) | ATRCCR2 | |
| SCHEMBL3461741 | 0.81 | PIK3CD (0.55) | ATRPIK3CDPIK3CAPIK3CGPIK3CB | |
| SCHEMBL3460193 | 0.81 | DRD4 (0.57) | CCR2DRD2DRD4HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501514-B1 | PROTEIN KINASE MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2012-12-19 | — | — | EP | claimed |
| US-20060211709-A1 | Protein kinase modulators and methods of use | EXELIXIS, INC. | 2006-09-21 | — | — | US | claimed |
| EP-1501514-B1 | PROTEIN KINASE MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2012-12-19 | — | — | EP | disclosed |
| US-7704995-B2 | Protein kinase modulators and methods of use | EXELIXIS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-20060211709-A1 | Protein kinase modulators and methods of use | EXELIXIS, INC. | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211709-A1 | Protein kinase modulators and methods of use | GRK2, MAP4K2, MAPKAPK2 | ATR 556/4885CCR2 3708/4885DRD2 1533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.